Approved for use through 03/31/2007, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

mation unless it contains a valid OMB control number

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of infor Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) of 8

Complete if Known Application Number 10/533,420 Filing Date 04/29/2005 First Named Inventor Hongming Chen Art Unit 1743 Examiner Name Gakh Yelena Attorney Docket Number TPI5020USPCT1

			U. S. PATENT D		
Examiner Initiels*	Cite No.1	Document Number Number-Kind Code ^{2 of Ancomb}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevent Passages or Relevent Figures Appear
	-	Number-Kind Coda			i iguica Appeai
		US-			1
		US-			
	-	US-			
		US-			
		US-		-	
		US-			

		FOREIC	SN PATENT DOCU	IMENTS		\neg
Examiner Initiels*	Cite No.	Foreign Patent Document	Publication Date	Nama of Patentee or Applicant of Cited Document	Peges, Columns, Lines, Where Relevent Pesseges	
		Country Code ² "Number ⁴ "Kind Code ² (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Τ6
		WO 01/51010	03-16-2007	L-0-1-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-		
						_
		WO 98/52047	11-19-1998	AURORA BIOSCIENCES		
		WO 00/59627	10-12-2000	MILLENNIUM PHARMA		
		EP 0921396	06-09-1999	PFIZER		
		EP 0807811	11-19-1997	PFIZER		П
		EP 0882500	12-09-1998	SUMITOMO		

Examiner	Data	
Signature	Considered	
0.9	00110100100	

Examiner
Signature
Signatu "Exchanger," Initial if reference consistents, whether or not claims as an contemnance with MPPE 60°C Oraw in a through cultation of the in-conformance and not upon the conformance and not u Translation is attached.

Transaction and auto-time. This collection of information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentially is governed by SU.S.C. 122 and 37 CFR.1.1.8 this Collection is estimated to take 2 hours to complete including gathering, proparing, and submitting that completed application from the USFTO. Then will vary depending on the individual case. Any comments on the amount of time by our require to complete this form and/or suggestions for reducing this burden, submitted be sent to the Chef Information Officer, U.S. Petent and Trademark Office, P.O. Box. 1490, Alexandrix, V.2.2 213-1450. D.O. NOT SEND FEES OR COMPLETE DEFORM STOTHIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) of 8

Sheet 4

ı	Con	ipiete ii Kilowii
r	Application Number	10/533,420
Γ	Filing Date	04/29/2005
Γ	First Named Inventor	Hongming Chen
	Art Unit	1743
r	Examiner Name	Gakh, Yelena
t	Attorney Docket Number	TPI5020USPCT1

			U. S. PATENT D	OCUMENTO	
Examiner Initials*	Cite No.	Document Number	Publication Data MM-DD-YYYY	Name of Patentes or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (FArrows)}			i igules Appeal
		US-			
		US-			*
		US-			
		US-			
		US-			
	1	US-			<u> </u>
		US-			
		US-	1		
		US-	1		
		US-	1 1		

			IGN PATENT DOCU			_
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Nama of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
	140.	Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Or Relevant Figures Appear	T ⁰
		EP 0553539	08-04-1993	SCHERING		
		EP 1174183	01-23-2002	SYMYX TECHNOLOGIES		
-		EP 1174185	01-23-2002	SYMYX TECHNOLOGIES		
		EP 1186892	03-13-2002	SYMYX TECHNOLOGIES		

1	Examiner Signature	Date Considered	

"EXAMINEST final if reference considered, whether or not calable is in conformance with MEPP 505. Drive him through battering it is conformance and more considered include copy of his form with rest communication to applicat." A physical value upon calable designation number (optional). "See Kines Codes of USF1O Patent Documents at www.uspido.gov or MEPP 901.04. "Earler Office that issued the document, by the two-letter code (WIPO Standard ST3)." For Japanese patient document, it is included not for layer of the Tempor or must preced the special number of the patient document. They considered in the constraints of the constraints of the constraints." the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

Transaction assurance.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) are application. Confidentially is governed by 35 U.S. C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complet unduring generating, preparing, and submitting the completed application from the USFTO. Time Will large depending onto the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for recturing this burden, should be sent to the Chef Information Officer, U.S. Petent and Trademark Office, P.O. 80s. 1480, Asserbaric, W.2. CERFSTAND. ON ONE SEND FEES OR COMPLETE OFFICIAL FOR THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
Trademark Office: U.S. DEDARTMENT OF COMMISSION

	der the Paperwork Re	duction A	ct of 1995, no persons ar		n of information unless it contains a valid OMB control number. Complete if Known
Substitu	18 10r 10fm 1449/P10			Application Number	10/533,420
INF	ORMATION	N DIS	CLOSURE	Filing Date	04-29-2005
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Hongming Chen
	(Use es menv sh	oote se e	occessed.	Art Unit	1743
	lose es meny su	eets as n	ocossary)	Examiner Name	Gakh, Yelena
Sheet	5	of	8	Attorney Docket Number	TPI5020USPCT1

Examiner Initials*	Cite No.1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BOWTELL, D., "Options available-from start to finish-for obtaining expression data by microarray", Nat Genet, 21 (1 Supp), pgs. 25-32 (1999)	
		BERGLUND et al., "Screening chemical and physical stability of drug substances", J. Phatmac. Biomed. Analysis, 1990, V. 8, No8-12, pp. 639-643	
		BEVAN et al., "A High Throughput Screening Method for the Determination of Aqueous Drug Solubility", Anal. Chem., 2000, v. 72, pp. 1781-1787	
		BYRN et al., Pharmaceutical solids: a strategic approach to regulatory considerations", Pharmaceutical Research, 1995, v. 12, No. 7, pp. 945-54	
		CHANDLER et al., "High-throughput Screening Techniques for Pre-formulation: Salt Selection and Polymorph Studies", Acta Cryst., 2002, A58, (Supplement) C9	
		CHAYEN et al., "Microbatch crystallization under oil-a new technique allowing many small-volume crystallization trials", J. of Crystal Growth, 122: pgs. 176-80 (1992)	
		COX et al., "An investigation of protein crystallization parameters using successive automated grid searches (SAGS)", J. of Crystal Growth, 90: pgs. 318-324 (1988)	
		CRAW et al., "Case based design for Tablet Formulation", proc. 4th Eur. Workshop on Case based Reasoning, pgs. 358-369 (1998)	
		CREESE, "Receptor Binding as a Primary Drug Screen", Neurotransmitter Receptor Binding, 2nd Ed., Ch. 9, pgs. 189-233 (1985)	
		ECKSTEIN et al., Unattended, Robotic Drug-Release Testing of Enterically Coated Aspirin*, Anal. Chem., 58: pgs. 2316-2320 (1986)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to epplicant.

considered. Include copy of the form with next communication to applicant.

In Applicant's usery calculation designation in number (piptional). Applicant is not placed achors much here if English larguage Translation is attached. In Applicant is not placed and the placed achors in Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)

Approved for use through 09/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are Substitute for form 1449/PTO	e required to respond to a collection	of information unless it conteins e valid OMB control number. Complete if Known
Substitute for form 1449/PTO	Application Number	10/533,420
INFORMATION DISCLOSURE	Filing Date	04-29-2005
STATEMENT BY APPLICANT	First Named Inventor	Hongming Chen
(Use as many sheets as necessary)	Art Unit	1743
(osc as many sheets as necessary)	Examiner Name	Gakh, Yelena
Sheet 6 of 8	Attorney Docket Number	TPI5020USPCT1

Examiner Initials*	Cite No.1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Food and Drug Administration, "International Conference on Harmonisation: Draft Guideline on Impurities" Federal Register 62: pgs. 24302-09 (1997)	
		GARDNER, "Application of High-Throughput Technologies to Drug Substance and Drug Product Development", FOCAPO, 12 January 2002	
		GEORGE et al., "Automated dissolution testing of sustained release tablets", American Laboratory 20: pgs. 106-112 (1988)	
		GOLD et al., "Effects of Selective U.S.P. Talcs on Acetylsalicylic Acid Stability in Tablets", Journ. Pharm. Sci., 53(1), pgs. 52-54 (1964)	
		GORDON et al., "Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions", J. Med. Chem., 37(10), pgs. 1384-1401 (1994)	
		HILFIKER et al., Polymorphism - integrated approach from high-throughput screening to crystallization optimization", Journal of Thermal Analysis amd Calorimetry, 2003, v. 73,	
		IYER et al., "Studies on Instantaneous release of Drug Compounds for Microfluidic High-throughput Screening Applications", Polymer Preprints: ACS, Division of Polymer Chemistr	
		KORNBLUM, 'Stability Studies of Small Solid Dosage Forms", Drug & Cosmetic Industry, 1970, v. 106, No. 4, pp. 141-146	
		LENCZEWSKI et al., "Automated Screening Method for Determining Optimum Preservative Systems", Journal of AOAC International, 81: pgs 534-9 (1998)	
		LENNERNAS, "Human Intestinal Permeability", Journal of Pharm. Sci., 87: pgs. 403-410 (1998)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Exclusive: Initial inference contacted, whether or led classion is in conformace with which the size of the conformace and in which the size of the conformace and in Applicant surple. In the conformace are conformation and in the conformace are conformation and in the conformace are conformation and in the conformation is required to obtain or retein a benefit by the public which is to file (and by the USPTO opposition) for processal in application. Confidentially is governed by 3 U.S. 1.2 and 9.7 CPT 1.1.4. This collection is estimated to the 2 hours to complete, including to processal in application. Confidentially is governed by 3 U.S. 1.2 and 9.7 CPT 1.1.4. This collection is estimated to the 2 hours to complete, including to processal in application. Confidentially is governed by 3 U.S. 1.2 and 9.7 CPT 1.1.4. This collection is estimated to the 2 hours to complete, including the confidence of the confident of the confident in the confidence of the confident of the confidence of the confident of the confide Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (04-07)

Approved for use through 09/30/2007. OMB 0551-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	Complete if Known		
	Application Number	10/533,420	
INFORMATION DISCLOSURE	Filing Date	04-29-2005	
STATEMENT BY APPLICANT	First Named Inventor	Hongming Chen	
(Use as many sheets as necessary)	Art Unit	1743	
(osc as many sheets as necessary)	Examiner Name	Gakh, Yelena	
Sheet 7 of 8	Attorney Docket Number	TPI5020USPCT1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (When appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		LIPINSKI et al., "Aqueous Solubility in Discovery, Chemistry, and Assay Changes", Methods and Principles in Medicinal Chemistry, 2003, 18 (Drug Bioavailability), pp. 215-231	
		LIPINSKi et al., "Experimental and computational approaches to estimate solubility and permeability in drug discovery", Advanced Drug Delivery, 2001, v. 46, pp. 3-26	
		LITTLECHILD et al., "Protein crystallization: magical or logical: can we establish some general rules?", J. of Physics, pgs. 111-118 (1991)	
		MARTIN et al., "Automation of Microtiter Plate-Chromogenic Substrate LAL Endotoxin Assay Method", J. of Parenteral Science and Technology, 4: pgs. 61-6 (1986)	
		MCFARLAND et al., "Combinatorial approaches to materials discovery", Trends Biotechnol., 17(3): pgs. 107-115 (1999)	
		MEHTA, "Issues and approaches for improving the solubility and bioavailability of poorly water soluble compounds", Bulletin Technique Gattefosse, 1998, v. 91, pp. 65-72	
		MERE et al., "Miniaturized FRET assays and microfluidics: key components for ultra-high-throughput screening", August 1999 DDT, 4(8), pgs. 363-369	
		MERRITT, A.T., "Uptake of new technology in lead optimization for drug discovery", 1998 DDT, 3(11), pgs. 505-510	
		MORELOCK et al., "Estimation and Correlation of Drug Water Solubility with Pharmacological Parameters Required for", J. Pharm. Sci., 1994, v. 83, No. 7, pp. 498-52	
		PROMEGA, Inc., "Cell Titer 96 AQueous One Solution Cell Proliferation Assay", 1996 Neural Notes, 11(3), 15	

Examiner Signature		Date Considered	
*EXAMINER: Ini	tial if reference considered, whether or not citation is in conformance with MPEP 60	9. Draw line through c	itation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

¹ Agricust surviva order in elegration number optionals 2 Applicant to glaze a check mark here if English lapsuage Transition is attached.

This solication of information is required by 37 CPR 1.8.1 his information is required to other or retain a benefit by the public which is to the (and by the USPTO to process) en explication. Confidentiality is governed by 30 U.S.C. 122 and 37 CPR 1.1.4. This collection is estimated to take 2 hours complete, including a public which is to the (and by the USPTO to process) en explication. Confidentiality is governed by 30 U.S.C. 122 and 37 CPR 1.1.4. This collection is estimated to take 2 hours complete, including a public Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (04-07)

Approved for use through 09/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

		luction Ac	t of 1995, no persons a	e required to respond to a collection	of information unless it contains a valid OMB control number. Complete if Known
Substitut	te for form 1449/PTO			Application Number	10/533,420
INFO	ORMATION	DIS	CLOSURE	Filing Date	04-29-2005
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Hongming Chen
	(Use es many she	uste ne n	acase and	Art Unit	1743
	(ose os many and		occasu, y)	Examiner Name	Gakh, Yelena
Sheet	8	of	8	Attorney Docket Number	TPI5020USPCT1

Cite No.1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	SHARMA et al., "Pharmaceutical and Physical Properties of Paclitaxel (Taxol) Complexes with Cyclodextrins", J. Pharm. Sci., 84, 10, pgs. 1223-1230 (1995)	
	SONG et al., "Controlled release of U-86983 from double-layer biodegradable matrices: effect of additives", J. Cont. Rel., 45(2), pgs. 177-192 (1997)	
	TAKAI et al., "Optimum Formulation of Griseofulvin/Hydroxypropyl Cellulose Solid Dispersions with Desireable", Chem. Pharm. Bull., 32(5), pgs. 1942-7 (1984)	
	WANG et al., "A New Ultra-high Throughput Method for Characterizing", Rapid Commun. in Mass Spectrom., 12, pgs. 1123-1129 (1998)	
	WARD et al., "Automatic preparation of protein crystals using laboratory robotics and automated visual inspection", J. of Crystal Growth, 90, pgs. 325-339 (1988)	
	1998 ARES Meeting Wine Tasting Onlinel XP002248070, Retrieved from the Internet: URL:http://www.aresnet.org/ARES/meetings 1998Wine.html retrieved on 7/15/2003	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citetion if not in conformance end not

^{**}EXAMINE** Initial inferience considered, wenter or not case on an incontentation with merch soul. Usew with through cleanur is an incontentation with merch soul. Usew with through cleanur is an incontentation and the property of the pro Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (09-06) Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademerk Office; U.S. DEPARTMENT OF COMMERCE

Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control numb

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APR 2:0 2007

(Use as many sheets as necessary)

Complete II Known					
Application Number	10/533,420				
Filing Date	04-29-2005				
First Named Inventor	Hongming Chen				
Art Unit	1743				
Examiner Name	Gakh, Yelena				
Attorney Docket Number	TPI5020USPCT1				

Sheet		1 01 0		Attorney Docket Number	TFI302003FCTT
			U O DATEN	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Docum	
		US- 3,899,011	08-12-1975	Curtiss	
		US- 5,859,703	01-12-1999	Aldridge et al.	
		US- 5,417,923	05-23-1995	Bojanic et al.	
		US- 4,399,687	08-23-1983	Collins	
		^{US-} 5,843,767	12-01-1998	Beattie	
		US- 5,985,214	11-16-1999	Stylli et al.	
		US- 5,490,415	02-13-1996	Mak et al.	
		US- 5,503,843	04-02-1996	Santus et al.	
		US- 6,271,038	08-07-2001	Liu et al.	
		US- 6,296,673	10-02-2001	Santarsiero et al.	
		^{US-} 4,808,705	02-28-1989	Ferris, R.	
		US- 5,746,982	05-05-1998	Saneii et al.	
		US- 2001/0016631	08-23-2001	Freitag et al.	
		US- 2001/0055775	12-27-2001	Schultz et al.	
		us- 2002/0023507	02-28-2002	Hajduk et al.	
		US- 2002/0029621	03-14-2002	Hajduk et al.	
		US- 2002/0032531	03-14-2002	Mansky et al.	
		US- 2002/0037647	03-28-200	Hwang et al.	
		US- 2002/0048610	04-25-2002	Cima et al.	

	FOREIGN PATENT DOCUMENTS						
Exeminer Cite Initiels* No.	Foreign Petent Document	Publication Date	Neme of Patentee or Applicant of Cited Document	Peges, Columns, Lines, Where Relevent Passeges			
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevent Figures Appear	T	
		WO 94/11489	05-26-1994	BIOLOG, INC.			
		WO 96/06842	03-07-1996	PFIZER LIMITED			
		WO 96/16078	05-30-1996	PFIZER LIMITED			
		WO 99/08112	02-18-1999	SUPRATEK PHARMA INC.			
		WO 98/40159	09-17-1998	TREGA BIOSCIENCES, INC			
		WO 98/47613	10-29-1998	SYMYX TECHNOLOGIES			

Examiner	Date	
Examiner Signature	Considered	

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. *Applicant's unique citation designation number (options)*-35e Knisto October 1957FO Patent December 31 www.periop.copy or MPEP 90.00 in. *Enter Office that issued the document, by the No-tester code (NPPO Standard ST.3). *For Japanese parent document, he indication of the year of the reign of the Engineer must proceed the conformation for the patent document. *Yind of document may be applicated as a check mark here! Telligible integrages. Translation is attached.

Intrastations statistical.

Intrastations of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain e benefit by the public which is to file (and by the USFTO to process) an application. Confidentiality is governed by 38 USC, 122 and 37 CFR 1.14. This collection is estimated to late X but to complete to complete the store of the USFTO time with very depending upon the individual case. Any comments on the amount of time you require to complete this form ender suggestion for motivating this burrien, should be sent to the Chef information Officer, US Patent and Tadestanck (Dies, P. O. Bos 1456, Mexandrien, W 23231455). OO NOT SENESS OR COMPLETED FORMS TO THIS ADDRESS. SENIOR. TO: Commissioner for Petents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent end Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information uriess it contains a said CMB control number.

Substitute for form 1448/PTO Application Number 10/533,420

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as mony sheets as necessary)

Sheet 2 of 8

Complete if Known				
Application Number	10/533,420			
Filing Date	04/29/2005			
First Named Inventor	Hongming Chen			
Art Unit	1743			
Examiner Name	Gakh, Yelena			
Attorney Docket Number	TPI5020USPCT1			

U. S. PATENT DOCUMENTS									
Examiner Initials*	r Cite No.1	Document Number Number-Kind Code ^{2 (f snown)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Peges, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
		US- 2003/0162226	08-29-2003	Cima et al.					
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
	_	US-							
		US-		†··					
		US-			1				
		US							
		US-	<u> </u>						
		US-							
		US-							
	-	US-	—						
		US-							
		US-							

FOREIGN PATENT DOCUMENTS											
Examiner Initiels*	Cite No.	Foreign Patent Document	Publication Date	Name of Petentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevent Pessages Or Relevant Figures Appear	7°					
		Country Code ³ "Number * "Kind Code ⁵ (# known)	MM-DD-YYYY								
		WO 98/52614	11-26-1998	BOARD OF TRUSTEES OF							
		WO 99/04247	01-28-1999	SYMYX TECHNOLOGIES							
		WO 99/06814	02-11-1999	SARNOFF CORPORATION		Г					
		WO 00/03240	01-20-2000	CETEK CORPORATION							
		WO 00/29987	05-25-2000	UNIV OF MARYLAND		Γ					
		WO 02/31477	04-18-2002	SYMYX TECHNOLOGIES							

Examiner Signature /Yelena Gakh/	Date Considered	11/20/2008
----------------------------------	--------------------	------------

[&]quot;EXAMINET. Intial If inderence considered, whicher or not cellatin is in conformance with MPEP 800. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant." Applicant's unique citation designation number (optional). "See Knist Codes or SSPTO Per December 2009 of the Codes of the

The collection of information is required by 37 CFR 197 and 1.88. The information is required to obtain or retain a benefit by the public which is to fire (and NU SFTO to process) in application. Combined lay is governed by 35 U.S.C. 122 and 37 CFR 1.4. This collection is estimated to take 2 hours not by put USFTO to process) in application. Combined lay 16 upon served by 35 U.S.C. 122 and 37 CFR 1.4. This collection is estimated to take 2 hours not by put including gathering, preparing, and submitting the completed application form to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of fine you require to complete this form and/or suppassions for reducing this budder, should be sent to the Chief Information Cliner. U.S. Patient end Trademark Office, P.D. Sen 1450, Alexandrin, Va. 2231-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Sen 1450, Sen 1450,

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.